Patient Surveillance After Curative-Intent Treatment for Rectal Carcinoma


Study, year

Surveillance intensity

Number of patients randomized

Median observation time (months)

Overall recurrence rate (%)

Number of second bowel cancers

Radical reoperation rate (%)

5-year survival rate (%)

Ohlsson (1995)

Less

54

82

33

NR

17

67

More

53

32
 
29

75

Makela (1995)

Less

54

>60

39

NR

14

54

More

52

42
 
23

59

Schoemaker (1998)

Less

158

>60

NR

5

NR

70

More

167
 
3
 
76

Kjeldsen (1997)

Less

307

>60

26

3

NR

68

More

290

26

7
 
70

Pietra (1998)

Less

103

>60

19

1

10

58

More

104

25a

0

65

73b

Secco (2002)

Less

145

>60

53

NR

16

48

More

192

57
 
31

63



a p < 0.05

b p < 0.05



In 2013, Johnson et al.[12] summarized the then-current recommendations of the following institutions:



  • The National Comprehensive Cancer Network (Table 18.2).


    Table 18.2
    Rectal cancer; obtained from NCCN (www.​nccn.​org) on 1/28/12 [12]
































































     
    Years posttreatmenta
     

    1

    2

    3

    4

    5

    >5

    Office visit

    2–4

    2–4

    2

    2

    2

    0

    Serum CEA levelb

    2–4

    2–4

    2

    2

    2

    0

    Chest/abdominal/pelvic CTc

    1

    1

    1

    0–1

    0–1

    0

    Colonoscopyd, e

    1

    0–1

    0–1

    0

    0–1

    0–1

    Proctoscopyf, g

    2

    2

    2

    2

    2

    0

    PET-CT scan is not routinely recommended.


    NCCN guidelines were accessed on 1/28/12. There were minor quantitative and qualitative changes compared to the guidelines accessed on 4/10/07

    aThe numbers in the table indicate the number of times the modality is recommended during the indicated year post-treatment

    bFor T2 or greater lesions

    cIf patient is a potential candidate for resection of isolated metastasis

    dFor patients at high risk for recurrence (e.g., lymphatic or venous invasion by tumor, or poorly differentiated tumors)

    eColonoscopy in 1 year except if no preoperative colonoscopy due to obstructing lesion, colonoscopy in 3–6 months. If advanced adenoma (villous polyp, polyp >1 cm, or high grade dysplasia), repeat in 1 year. If no advanced adenoma, repeat in 3 years, then every 5 years

    fFor patients status post low anterior resection of the rectum

    gPatients with rectal cancer should also undergo limited endoscopic evaluation of the rectal anastomosis to identify local recurrence. Optimal timing for surveillance in not known. No specific data clearly support rigid versus flexible proctoscopy. The utility of routine endoscopic ultrasound for early surveillance is not defined


  • The American Society of Clinical Oncology (Table 18.3).


    Table 18.3
    Colorectal cancer; obtained from ASCO (www.​asco.​org) on 1/28/12 [12]


































































     
    Years posttreatmenta
     

    1

    2

    3

    4

    5

    >5

    Office visit

    2–4

    2–4

    2

    2

    2

    0b

    Serum CEA levelc, d

    4

    4

    4

    0

    0

    0

    Chest/abdomen CTe

    1

    1

    1

    0

    0

    0

    Colonoscopyf, g

    1

    0

    1

    0

    1

    0-1

    Flexible proctosigmoidoscopyh

    2

    2

    2

    2

    2

    0

    Routine blood tests (i.e., CBC, LFTs), fecal occult blood testing, yearly chest x-rays are not recommended.

    Use of molecular or cellular markers should not influence the surveillance strategy.


    ASCO guidelines were accessed on 1/28/12. There were no significant changes compared to the guidelines accessed on 10/31/07

    aThe numbers in the table indicate the number of times the modality is recommended during the indicated year post-treatment

    bPhysician visit after 5 years at the discretion of the physician

    cFor patients with stage II or III disease if the patient is a candidate for surgery or systemic therapy

    dSince fluorouracil-based therapy may falsely elevate CEA values, waiting until adjuvant treatment is finished to initiate surveillance is advised

    eFor patients who are at a higher risk or recurrence, and who could be candidates for curative-intent surgery. A pelvic CT scan should be considered for rectal cancer surveillance, especially for patients who have not been treated with radiotherapy

    fAll patients with colon and rectal cancer should have a colonoscopy for pre- and perioperative documentation of a cancer- and polyp-free colon. If normal at 3 years, once every 5 years thereafter

    gFor colorectal cancer patients with high-risk genetic syndromes, the physician should consider the guideline published by the American Gastroenterology Association

    hFor rectal cancer patients who have not received pelvic radiation


  • The European Society for Medical Oncology (Table 18.4).


    Table 18.4
    Rectal cancer; obtained from ESMO (www.​esmo.​org) on 1/28/12 [12]
























































     
    Years posttreatmenta
     

    1

    2

    3

    4

    5

    >5

    Office visit

    2

    2

    0

    0

    1

    0–1

    Rectosigmoidoscopy

    2

    2

    0

    0

    0

    0

    Colonoscopyb

    1

    0

    0

    0

    1

    0–1

    Imaging of liver, lungs

    1

    0

    1

    0

    0

    0

    The value of regular clinical, laboratory and radiological examinations are not known.


    ESMO guidelines were accessed on 1/28/12. There were minor quantitative and qualitative changes compared to the guidelines accessed on 10/31/07

    aThe numbers in the table indicate the number of times the modality is recommended during the indicated year post-treatment

    bA completion colonoscopy, if not done at the time of diagnostic work-up (e.g. if obstruction was present), should be performed within the first year. History and colonoscopy with resection of colonic polyps every 5 years


  • The National Institute for Clinical Excellence (NICE) of the United Kingdom (Table 18.5).


    Table 18.5
    Colorectal cancer; obtained from NICE (www.​nice.​org.​uk) on 1/28/12 [12]




































     
    Years posttreatmenta
     

    1

    2

    3

    4

    5

    >5

    Office visitb, c

    ≥2

    ≥2

    ≥2

    0

    1

    0

    Serum CEA level

    ≥2

    ≥2

    ≥2

    0

    Only gold members can continue reading. Log In or Register to continue

    Stay updated, free articles. Join our Telegram channel

    Jan 29, 2017 | Posted by in GASTROENTEROLOGY | Comments Off on Patient Surveillance After Curative-Intent Treatment for Rectal Carcinoma

    Full access? Get Clinical Tree

    Get Clinical Tree app for offline access